Navigation Links
Beaumont Patients 1st to get Next Generation of Radiation Treatment
Date:9/20/2007

ROYAL OAK, Mich., Sept. 20 /PRNewswire/ -- Cancer patients at Beaumont Hospitals are the first in the world to be treated with the next generation of radiation therapy that is painless, faster, more accurate and precise than other treatments.

Beaumont doctors and physicists invented and patented the new technology, Omnibeam(R). The $3.3-million machine is manufactured in England by Elekta, which is headquartered in Stockholm. The first patient was treated on Sept. 10.

The painless treatment takes about 20 minutes and requires no implants or invasive procedures to prepare for therapy. It can be used to treat cancer of the breast; prostate; lungs; and head and neck, as well as other cancers. It is specially designed for the treatment of tumors deep within the body.

Omnibeam(R), a robotic technology, uses highly accurate, real-time CT imaging that automatically adjusts the radiation field during treatment to account for a patient's external movements - and the natural repositioning of internal organs - from day to day or even moment to moment. Omnibeam(R) also uses robotic technology to adjust the treatment table on which a patient lies to provide pinpoint accuracy of treatment. Adjusting the radiation field and treatment table means the radiation treatment is precisely targeted to kill cancer cells, destroying them without harming surrounding healthy tissue or organs. The patient has better cancer control and fewer undesirable side effects as a result.

"Omnibeam(R) is a dramatic new clinical advance in radiation therapy for cancer. The combination of improved imaging coupled with robotic technology is vastly better than other radiation machines for cancer therapy," says Alvaro Martinez, M.D., corporate chairman of Radiation Oncology for Beaumont Hospitals. "It uses advanced imaging technology, is faster, can treat from very small to very large, irregularly shaped tumors and does not require placement of metal implants as with other therapies. Its robotic component tracks a patient's movements on a real-time basis and corrects the treatment accordingly."

Dr. Martinez was inspired to "marry" CT imaging with a medical linear accelerator when, while attending a medical symposium in Dearborn, he stumbled upon a meeting of Ford Motor Company automotive engineers who were using imaging to detect defects in engine blocks. It took more than five years for him and his team to adapt and perfect the auto technology for cancer radiation treatment.

Contact Beaumont's Radiation Oncology department at 248-551-8819 for more information about Omnibeam(R).

When the diagnosis is cancer and radiation treatment is needed, the hospitals' Radiation Oncology department offers the most advanced therapies, including intensity modulated radiation therapy and image-guided radiation treatment, whether external-beam or brachytherapy (internal radiation). The department is a world-renowned pioneer in advancing radiation therapy that is more precise, paving the way for better cancer control and fewer undesirable side effects.


'/>"/>
SOURCE William Beaumont Hospitals
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Hematology Analyzers Simple, Sophisticated Technology Serving All Patients
2. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
3. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
4. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
5. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
6. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
7. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
8. TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
9. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
10. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
11. Skin Rash Actually Signifies Better Outcomes for Pancreatic and Lung Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... Mass. , April 20, 2017  RXi ... developing innovative therapeutics that address significant unmet medical ... data from the Company,s consumer product development program, ... at the Society for Investigative Dermatology (SID) 76 ... to advance and promote the sciences relevant to ...
(Date:4/20/2017)... WOONSOCKET, R.I. , April 20, 2017 /PRNewswire/ ... (NYSE: CVS), today unveiled a new store design ... new assortment of healthier food, health-focused products and ... the store to help customers discover new offerings. ... represent the next evolution of the customer experience ...
(Date:4/20/2017)... AMSTERDAM , April 20, 2017  AbbVie ... that 99 percent (n=145/146) of chronic hepatitis C ... 4, 5 or 6 and compensated cirrhosis (Child-Pugh ... post-treatment (SVR 12 ) with its investigational, pan-genotypic ... rates were seen following 12 weeks of ...
Breaking Medicine Technology:
(Date:4/24/2017)... ... April 24, 2017 , ... Ridgecrest Herbals makes it a point ... strategies to reduce waste, and support renewable energy. They believe this is a crucial ... to find solutions for health issues, and maintain that destroying the environment in the ...
(Date:4/24/2017)... , ... April 24, 2017 , ... The California Dental ... in charitable dental services to 1,961 people during the April 22-23 event at the ... charge to Californians who experience barriers to care, CDA Cares educates the public and ...
(Date:4/24/2017)... ... April 24, 2017 , ... The world-class designers of ... bring their novel lifesaving device for the everyday use of parents worldwide. It ... designed to read a child’s vital signs, and detect unusual symptoms or physical ...
(Date:4/24/2017)... ... April 24, 2017 , ... In 2017, up to 78,000 ... 25,000 of them will be malignant.(1) As research into precision medicine continues, both ... model in the diagnosis and treatment of brain tumors. Healthcare facilities that are ...
(Date:4/24/2017)... ... , ... Come to PAINWeekEnd (PWE) Tampa on May 20 and 21, at ... exciting 2-day program. , An attendee at a recent PAINWeekEnd said, "Very helpful, ... the course entitled Ain't Misbehavin': Decreasing and Managing Pain Patient Aberrant Behavior, presented by ...
Breaking Medicine News(10 mins):